Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:2703
Structure:
Synonyms:
(1,3)Benzodioxolo(5,6-c)phenanthridinium, 1,2-dimethoxy-12-methyl-,
(1,3)Benzodioxolo(5,6-c)phenanthridinium, 1,2-dimethoxy-12-methyl-, hydroxide (9CI)
1,2-Dimethoxy-12-methyl(1,3)benzodioxolo(5,6-c)phenanthridinium
1,2-Dimethoxy-12-methyl-12lambda~5~-[1,3]benzodioxolo[5,6-c]phenanthridine hydrochloride
1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium
1,2-Dimethoxy-12-Methyl[1,3]benzodioxolo[5,6-C]phenanthridin-12-Ium
1,2-Dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridinium
1,2-Dimethoxy-N-methyl(1,3)benzodioxolo(5,6-c)phenanthridinium chloride
34316-15-9
34316-15-9 (Parent)
3895-92-9
3895-92-9 (chloride)
478-03-5
478-03-5 (hydroxide)
AC1L1E9W
AIDS-002650
AIDS002650
Benzophenanthridine alkaloid
BRD-K87904882-001-02-3
BSPBio_001558
C12227
C21H18NO4
CCG-204336
Chelerythrine
Chelerythrine aurichloride
Chelerythrine chloride
Chelerythrine hydroxide
Chelerythrine, hydroxide, compd. with gold chloride (AuCl3) (8CI)
Chelerythrinium hydroxide
CHEMBL13045
CTI
EINECS 251-930-0
Helleritrine hydroxide
HMS1791N20
HMS1989N20
Lopac-C-2932
Lopac0_000241
LS-174464
MEGxp0_001953
NCGC00015225-01
NCGC00015225-02
NCGC00015225-03
NCGC00015225-04
NCGC00015225-05
NCGC00015225-06
NCGC00015225-07
NCGC00162102-01
NCGC00162102-02
NCGC00162102-03
NCGC00162102-04
NCGC00162102-05
nchembio873-comp36
NCI60_003349
NCI60_041672
NSC 76023
NSC646662
NSC646662 (CHLORIDE SALT)
Toddalin
Toddaline
ZINC03872044
[1,3]Benzodioxolo[5,6-c]phenanthridinium, 1,2-dimethoxy-12-methyl-

Target

show target details
Uniprot ID:Q7TNA8_RAT
Synonyms:
L-lactate dehydrogenase
EC-Numbers:1.1.1.27
Organism:Rat
Rattus norvegicus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

10603424
Protein kinase C inhibitors abolish the increased resistance of diabetic rat heart to ischemia-reperfusion injury.. C H Moon; Y S Jung; S H Lee; E J Baik (1999) The Japanese journal of physiology display abstract
Protein kinase C (PKC) has been implicated in ischemic preconditioning, but whether it plays a role in the cardioprotection observed in the diabetic heart is not known. We assessed the possible role of PKC by investigating whether the inhibition of PKC with staurosporine (Stau, 0.01 microM) or chelerythrine (Chel, 1 microM) can abolish the increased resistance to ischemia (25 min)-reperfusion (30 min) injury in Langendorff perfused hearts from streptozotocin-induced 4-week diabetic rats. In the diabetic heart, pre-ischemic left ventricular developed pressure (LVDP), double product (DP: LVDPxheart rate/1,000), +/- dP/dt(max) and coronary flow rate (CFR) were all reduced compared to the control. The pretreatment with Stau or Chel significantly improved these parameters. The post-ischemic contractile function was recovered to a greater extent in the diabetic heart (116.9 +/- 20.5% of pre-ischemic DP) than in the control (23.3 +/- 2.3% of pre-ischemic DP), indicating the increased resistance of the diabetic heart to ischemia-reperfusion injury. The treatment with Stau or Chel abolished the enhanced recovery in the diabetic heart (36.0 +/- 14.6 and 54.1 +/- 12.8% of pre-ischemic DP, respectively). The reduction in post-ischemic end diastolic pressure (EDP) and lactate dehydrogenase (LDH) release in diabetes (13.5 +/- 2.5 mmHg and 27.2 +/- 6.2 U/g heart) compared to the control (55.8 +/- 2.9 mmHg and 60. 3 +/- 5.7 U/g heart) was significantly (p